Rohera Healthcare & Technology Private Limited: website

emedica.in

閱讀原始來源

閱讀採用這份來源的內容

1 篇內容
  1. Rohera Healthcare & Technology Private Limited

    公司知識更新日期

    Rohera Healthcare and Technology Private Limited: “Rohera Healthcare and Technology Pvt. Ltd. manufactures eMedica, a patented non-invasive bioelectronic adjuvant therapy device using VCF (Voltage-Current-Frequency) technology validated in 37 institutions with 4,651+ patients.”

    • What is eMedica?

      “eMedica is a non-invasive bioelectronic adjuvant therapy device by Rohera Healthcare and Technology Pvt. Ltd. It uses patented VCF (Voltage-Current-Frequency) technology to restore cellular electrical balance as a complement to prescribed medical treatment. It is NOT a replacement for medicine — it is adjuvant therapy.”

      在公司資料中查看
    • Is eMedica a medical device?

      “Yes. eMedica is a registered medical device certified by CDSCO (India), CE Marked, ISO compliant, and holds US Patent 12,226,183 B2 (also filed in Japan, Eurasia, UAE, Saudi Arabia and 90+ countries).”

      在公司資料中查看
    • What conditions does eMedica support as adjuvant therapy?

      “eMedica has been studied as adjuvant therapy across multiple chronic-care, rehabilitation, and recovery protocols including diabetes support, cardiovascular conditions, neurological disorders, pain management, respiratory conditions, kidney conditions, and cancer support — across 37 institutions in India with 4,651+ patients.”

      在公司資料中查看
    • Does eMedica cure or treat disease?

      “No. eMedica does not claim to cure, diagnose, or treat any disease. It is exclusively an adjuvant therapy device — designed to complement and support prescribed medical treatment, not to replace it. Always consult a qualified healthcare professional.”

      在公司資料中查看

    這份來源的其他資料

    • Rohera Healthcare and Technology Private Limited

      “Rohera Healthcare and Technology Pvt. Ltd. manufactures eMedica, a patented non-invasive bioelectronic adjuvant therapy device using VCF (Voltage-Current-Frequency) technology validated in 37 institutions with 4,651+ patients.”